Table 2.

A comparison of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) or grade 3 or more severe diagnoses (CIN3+) risks with 95% confidence intervals (95%CI) in women living with HIV (WLWH) and without HIV (HIV[−]), stratified on human papillomavirus (HPV) and cytology co-testing results. The first two row are the total population of WLWH and HIV[−] women. Risk estimates for paired WLWH and HIV[−] groups in which there were fewer than 30 WLWH and no cases of CIN2+ for those WLWH are not included. “Any” is for any result e.g., positive (Pos), negative (Neg), or not available (n/a).

HIV Status	HPV Result	Cytology Result	N_Total	N_informative^**	End point	N_Cases	Immediate (Prevalent)		1-Year Cumulative Risk		3-Year Cumulative Risk		5-Year Cumulative Risk		^{p_CIN2+^†}╱_{p_CIN3+^‡}
HIV Status	HPV Result	Cytology Result	N_Total	N_informative^**	End point	N_Cases	Risk (%)	95%CI (%)	Risk (%)	95%CI (%)	Risk (%)	95%CI (%)	Risk (%)	95%CI (%)	╱
WLWH	Any	Any	608	474	CIN2+	22	2.4	1.2–3.5	2.6	1.4–3.9	3.1	1.8–4.4	3.5	2.0–5.0	^0.01╱_0.24
WLWH			608	474	CIN3+^§	7	0.8	0.0–1.6	0.9	0.0–1.7	1.0	0.2–1.8	1.3	0.3–2.3
HIV [−]			67,488	39,398	CIN2+	907	0.8	0.7–0.9	1.2	1.1–1.3	1.4	1.3–1.5	1.6	1.5–1.8
HIV [−]			67,488	39,398	CIN3+	377	0.4	0.4–0.5	0.5	0.5–0.6	0.7	0.6–0.7	0.7	0.6–0.8
WLWH	Pos	Any	123	111	CIN2+	20	10.5	5.1–16	11.9	6.2–17.6	13.4	7.4–19.5	15.6	8.7–22.5	^0.53╱_0.38
WLWH			123	111	CIN3+	7	3.6	0.2–7	3.6	0.2–7	4.3	0.6–7.9	5.8	1.0–10.6
HIV [−]			4355	3712	CIN2+	665	11.2	10–12.4	13.8	12.7–14.8	16.2	15–17.3	17.9	16.6–19.1
HIV [−]			4355	3712	CIN3+	298	5.4	4.5–6.2	6.6	5.8–7.3	7.4	6.6–8.2	8.0	7.1–8.9
WLWH	Neg		475	355	CIN2+	2	0.2	0–0.7	0.2	0–0.7	0.4	0–0.8	0.4	0–0.9	^0.76╱_n/a
WLWH			475	355	CIN3+^§	0	0.0	0.0–0.8^‡	0.0	n/a	0.0	n/a	0.0	n/a
HIV [−]			61,966	35,640	CIN2+	236	0.1	0–0.2	0.3	0.2–0.4	0.4	0.3–0.5	0.5	0.4–0.6
HIV [−]			61,966	35,640	CIN3+	77	0.1	0.1–0.1	0.1	0.1–0.1	0.2	0.2–0.2	0.2	0.2–0.2
WLWH	n/a		10	8	CIN2+	0									╱
WLWH			10	8	CIN3+	0									╱
HIV [−]			1152	44	CIN2+	6									╱
HIV [−]			1152	44	CIN3+	2									╱
WLWH	Any	Pos	84	79	CIN2+	19	14.4	6.7–22.1	16.5	8.4–24.6	18.7	10.1–27.4	22.0	12.0–32.0	^0.77╱_0.11
WLWH			84	79	CIN3+^§	5	3.8	0.0–8.0	3.8	0.0–8.1	4.6	0.3–8.9	6.4	1.0–11.8
HIV [−]			2615	2357	CIN2+	522	17.2	15.7–18.7	19.6	18.0–21.2	21.9	20.2–23.6	23.5	21.7–25.3
HIV [−]			2615	2357	CIN3+	234	8.5	7.4–9.7	9.6	8.4–10.8	10.4	9.1–11.7	11.0	9.6–12.3
WLWH		Neg^*	522	394	CIN2+	3	0.4	0–1.0	0.4	0–1.0	0.6	0–1.1	0.6	0–1.1	^0.50╱_0.43
WLWH			522	394	CIN3+^§	2	0.3	0.0–0.8	0.3	0.0–0.8	0.3	0.0–0.8	0.4	0.0–1.0
HIV [−]			64,713	36,981	CIN2+	383	0.2	0.1–0.2	0.4	0.4–0.5	0.6	0.5–0.7	0.8	0.7–0.8
HIV [−]			64,713	36,981	CIN3+	133	0.1	0.1–0.2	0.2	0.1–0.2	0.3	0.2–0.3	0.3	0.3–0.3
WLWH		n/a	2	1	CIN2+	0									╱
WLWH			2	1	CIN3+	0									╱
HIV[−]			145	58	CIN2+	2									╱
HIV[−]			145	58	CIN3+	1									╱
WLWH	Pos	Pos	71	66	CIN2+	18	16.4	7.5–25.3	18.7	9.4–28.1	21.2	11.3–31.2	24.9	13.4–36.4	^0.77╱_0.21
WLWH			71	66	CIN3+^⁑	5	4.6	0.0–9.6	4.6	0.0–9.6	5.5	0.1–10.9	7.6	0.3–14.9
HIV [−]			2,249	2,081	CIN2+	494	19.5	17.8–21.2	22.2	20.4–24.0	24.8	22.9–26.7	26.6	24.6–28.7
HIV [−]			2,249	2,081	CIN3+	230	9.6	8.4–10.9	10.9	9.5–12.2	11.8	10.4–13.2	12.4	10.9–13.9
WLWH		Neg^*	52	45	CIN2+	2	2.5	0.0–6.9	2.6	0.0–6.5	2.8	0.0–7.2	3.0	0.0–7.4	^0.02╱_0.97
WLWH			52	45	CIN3+^⁑	2	2.2	0.0–6.5	2.2	0.0–6.5	2.6	0.0–7.0	3.4	0.0–8.7
HIV [−]			2,097	1,625	CIN2+	169	2.3	0.6–3.9	4.7	3.6–5.7	6.9	5.8–8.1	8.5	7.2–9.9
HIV [−]			2,097	1,625	CIN3+	67	0.8	0.0–1.9	1.9	1.2–2.6	2.7	2.0–3.5	3.3	2.4–4.2
WLWH		n/a	0	0	CIN2+	0									╱
WLWH			0	0	CIN3+	0									╱
HIV [−]			9	6	CIN2+	2									╱
HIV [−]			9	6	CIN3 +	1									╱
WLWH	Neg	Pos	11	11	CIN2+	1	1.6	0.0–5.7	2.1	0.0–6.4	2.7	0.0–7.5	3.6	0.0–9.8	^0.59╱_n/a
WLWH			11	11	CIN3+	0	0.0	0.0–33.5^‡	0.0	n/a	0.0	n/a	0.0	n/a
HIV [−]			321	258	CIN2+	23	1.4	0.4–2.4	1.6	0.6–2.6	1.8	0.8–2.7	1.9	1.0–2.8
HIV [−]			321	258	CIN3+	11	1.0	0.0–2.2	1.0	0.0–2.2	1.1	0.0–2.3	1.1	0.0–2.3
WLWH		Neg^*	462	343	CIN2+	1	0.2	0.0–0.7	0.2	0.0–0.7	0.3	0.0–0.7	0.3	0.0–0.8	^0.44╱_n/a
WLWH			462	343	CIN3+	0	0.0	0.0–0.8^‡	0.0	n/a	0.0	n/a	0.0	n/a
HIV [−]			61,509	35,330	CIN2+	213	0.1	0.1–0.2	0.3	0.2–0.3	0.4	0.4–0.5	0.5	0.4–0.6
HIV [−]			61,509	35,330	CIN3+	66	0.1	0.0–0.1	0.1	0.1–0.2	0.2	0.1–0.2	0.2	0.1–0.2
WLWH		n/a	2	1	CIN2+	0									╱
WLWH					CIN3+	0									╱
HIV [−]			136	52	CIN2+	0									╱
HIV [−]					CIN3+	0									╱
WLWH	n/a	Pos	2	2	CIN2+	0									╱
WLWH			2		CIN3+	0									╱
HIV [−]			45	2	CIN2+	0									╱
HIV [−]			45		CIN3+	0									╱
WLWH		Neg	8	6	CIN2+	0									╱
WLWH			8		CIN3+	0									╱
HIV [−]			1107	26	CIN2+	1									╱
HIV [−]			1107		CIN3+	0									╱
WLWH		n/a	0	0	CIN2+	0									╱
WLWH			0		CIN3+	0									╱
HIV [−]			15	2	CIN2+	0									╱
HIV [−]			15		CIN3+	0									╱

Included atypical squamous cells of undetermined significance if the concurrent HPV test was negative.

^†

Differences in 5-year risk between WLWH and HIV[−] for CIN2+

Differences in 5-year risk between WLWH and HIV[−] for CIN3+

^‡

Poisson exact confidence interval

^⁑

Modeled in HPV+ subset

^§

Marginal analysis instead of weighted average

^**

N_informative refers to women who contributed to the risk estimations because they were diagnosed with CIN2+ or had a negative assessment in follow-up.